Roles
- Professor of Psychiatry and Behavioral Sciences
- Chief Director, Division of Psychology
- Vice Chair for Research
-
Biography
Philip D. Harvey, PhD is Leonard M. Miller Professor of Psychiatry and director of the Division of Psychology at the University of Miami Miller School of Medicine, as well as a senior Research health Scientist at the Department of Veterans Affairs. He started work at the University of Miami Miller School of Medicine in July, 2010.
He has served on several National Academy of Medicine Panels and headed a blue-ribbon panel jointly launched by the Social Security Administration and the National Institute of Mental Health with a goal of streamlining the process of award of social security disability to people with severe mental illness.
He has received a number of awards, including the Inaugural Schizophrenia International Research Society Clinical Scientist Distinguished Contributions award (2012), the 2014 Alexander Gralnick Schizophrenia Research award from the American Psychiatric Foundation, and the 2014 John Blair Barnwell award, the highest award for Clinical Research across all scientific disciplines from the US Department of Veterans affairs, and the 2021 Stanley Dean Award for Schizophrenia research from the American College of Psychiatrists.
His research has focused for years on cognition and everyday functioning and he has written on cognition in aging, aging in schizophrenia, and interactions with serious mental illness, aging and technology. He also been studying the effects of cognitive enhancing agents and cognitive and functional skills training in various conditions, including healthy aging, mild cognitive impairment, schizophrenia, dementia, bipolar disorders, and traumatic brain injury. His most recent work has focused on technology-based momentary assessments, with a focus on negative symptoms and everyday activities in schizophrenia and bipolar disorder. -
Education & Training
Education
-
Honors & Awards
-
Teaching Interests
Clinical Neuropsychology
Psychopathology
Aging -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Dean’s Faculty Awards: Celebrating Academic and Clinical Excellence
Digital Training Enhances Skills and Cognition
Department of Psychiatry and Behavioral Sciences Leads Conference Focused on Latest in Mental Health Treatment, Featuring Legendary Faculty
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 6 clinical trials.
-
A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia
- Principal Investigator: Philip Harvey
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The objective of the proposed study is to evaluate CT-155 clinical effectiveness, engagement with the study app, healthcare resource utilization, and safety in a pragmatic prospective setting as an adjunct to standard of care therapy in patients with negative symptoms in schizophrenia, including assessment of durability of effect and incremental benefit of an additional course of treatment. In addition, this study will evaluate the economic impact of treatment with CT-155.
- Principal Investigator: Philip Harvey
- Study Phase: TBD
- Enrollment Status: Open
-
Self-awareness and the ability to directly evaluate one's own abilities and performance are important for everyday functioning. We are using remote and in person assessments to examine people's daily activities as well as their ability to evaluate their memory performance. This study involves several weeks of daily self assessment and reports of everyday activities.
- Principal Investigator: Philip Harvey
- Study Phase: Other
- Enrollment Status: Closed
-
To treat 201 participants with psychotic disorders with the iTEST intervention using the optimal dose determined from the trial 1 (R61) phase. In this phase, we will compare iTEST IA-training to a coaching-only control. The control condition will include time-equivalent coaching in goal setting and will include mobile cognitive testing but will not include any elements of introspective accuracy remediation, including psychoeducational content and application of IA principles in coaching or mobile training regarding introspective accuracy.
- Principal Investigator: Philip Harvey
- Study Phase: TBD
- Enrollment Status: Open
-
There is limited evidence from epidemiological studies about the cognitive benefits of crosswords in older adults with mild cognitive impairment. There are a few small-scale clinical trials showing limited efficacy for crosswords that typically were not the primary targeted intervention. Our previous study of 109 individuals with mild cognitive impairment was supported by the initial project for this NIA-supported grant renewal: the COG-IT study. In COG-IT, there was efficacy for computerized crosswords compared to computerized cognitive training with cognitive games, but there was no control group. We will conduct a new study, WORDFIT, at 4 sites: Columbia University, Duke University, University of Miami, and University of Washington. The study will compare three treatment conditions for 78 weeks: crossword puzzles 4 times/week, crossword puzzles once/week, and health education. Crosswords will be done at home on an electronic web-based platform provided and maintained by the company Cognifit.
- Principal Investigator: Philip Harvey
- Study Phase: TBD
- Enrollment Status: Open
-
A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-3)
- Principal Investigator: Philip Harvey
- Study Phase: Phase 3
- Enrollment Status: Closed
